Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Kalbe Farma (KLBF IJ)
Watchlist
163
Analysis
Health Care
•
Indonesia
PT Kalbe Farma Tbk produces and develops pharmaceutical products for human and animal healthcare. Through its subsidiaries, the Company also operates in the pharmaceutical, health food, and packaging industries.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
19 Dec 2024 09:41
•
Broker
Consumer: FY25 Outlook: Growth Drivers from Supported Purchasing Power and Strategic Pricing
We expect higher minimum wages in FY25 and a positive impact from purchasing power and govt’s meal program to create more jobs.
BRI Danareksa Research
Follow
145 Views
Share
bullish
•
Thematic (Sector/Industry)
•
12 Oct 2024 06:41
•
Broker
Consumer: Sustained Solid Core Profit Growth on Stable Margins, in Line with Our and Consensus
We estimate 3Q24/9M24 sector revenue growth of +2.6%/+4% yoy and 9M24 operating profit of +7% yoy, in line with our and cons. est.
BRI Danareksa Research
Follow
364 Views
Share
bullish
•
Thematic (Sector/Industry)
•
10 Oct 2024 18:37
•
Broker
Consumer: 3Q24 Preview: Sustained Solid Core Profit Growth on Stable Margins
We estimate 3Q24/9M24 sector revenue growth of +2.6%/+4% yoy and 9M24 operating profit of +7% yoy, in line with our and cons. est.
BRI Danareksa Research
Follow
240 Views
Share
bullish
•
Thematic (Sector/Industry)
•
28 Aug 2024 18:59
•
Broker
Consumer: Sticking with the Winners Amid Lingering Challenges (OVERWEIGHT)
Amid continued downtrading and limited catalystsin 3Q24, we expect regional elections and social aid to support consumption spending.
BRI Danareksa Research
Follow
198 Views
Share
bullish
•
Thematic (Sector/Industry)
•
09 Jul 2024 18:52
•
Broker
Consumer: Expect Solid Core Profit Growth on Better Margins, Revenue Growth May Remain Soft
We estimate sector’s 2Q24 core profit to grow at a healthy doubledigit rate, but expect weak rev. growth (2.8% yoy/ -15.8% qoq)
BRI Danareksa Research
Follow
172 Views
Share
Previous
1
2
3
4
5
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x